Core One Labs will present its proprietary biosynthetic product



VANCOUVER, British Columbia, July 17, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core A“or the”Company“) is pleased to announce that Dr. Robert EW Hancock, Chairman of the Board of the Company and CEO of its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan“) will present at a virtual town hall hosted by the company on Wednesday, August 4, 2021 at 1:30 p.m. PST / 4:30 p.m. ET / 10:30 p.m. CET.

The Virtual Town Hall event will feature a presentation by Dr. Hancock on the status of biosynthetic psilocybin production by Vocan and will include live video from the company’s operating laboratory in Victoria, BC. Dr Hancock will also answer questions from investors.

2021 has been an important year for Core One Labs, and our teams have been focused on building a business that we believe is truly setting a precedent in the field of psychedelics. Our multi-faceted business model envisions a business that addresses the full cycle of psychedelics; from research into the development of proprietary products, to the development and implementation of appropriate clinical trial research, as well as to meeting the treatment needs of clients on their various journeys to achieve sustainable mental well-being ,Said Joel Shacker, CEO of the company.

It is a vision to which each member of our team is committed and to which they work diligently. Over the past few months, the company has taken important milestones, and I am very pleased to announce that our Company President, Psychedelics as an alternative medicine visionary and world-renowned scientist, Dr. Robert Hancock Virtual Town Hall for providing all market players with an in-depth overview of some of our exciting developments.

About Core One Labs Inc.

Core One is a biotechnology and technological life science research company focused on commercializing psychedelic drugs through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent pending thin film oral tape (the “Technology”) that instantly dissolves when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also owns a stake in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, the R&D related to psychedelic treatments and new drug therapies, the Company intends to obtain regulatory research approval for the advancement of treatments derived from psychedelics. for mental health disorders.

Core One Labs Inc.

Joel shacker
Chief executive officer

FOR MORE INFORMATION PLEASE CONTACT:
[email protected]
1-866-347-5058

Disclaimer:

The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.

The information contained in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the control of the Company. These factors include, among others: risks and uncertainties associated with the Company’s limited operating history and the need to comply with strict regulatory regulations. Therefore, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Unless required by applicable securities legislation, the Company assumes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelics in the jurisdictions in which it operates. While Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate legalizing psychedelics for recreational purposes. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.


Previous Auto repair shops profit - The Lima News
Next Final Frontier has been there for 17 years, flights from Spaceport America are now a turning point for the NM economy ”Albuquerque Journal

No Comment

Leave a reply

Your email address will not be published.